The BCG shortage, overuse of cystoscopy, and hematuria evaluation approaches are among the topics of the most-read Urology Times articles from 2019 on bladder cancer.
Hematuria evaluation: Evidence for optimal practice?
In this blog post, Adele M. Caruso, DNP, CRNP, summarizes current evidence and guidance for hematuria evaluation as it pertains to clinicians, including advanced practice providers.
Cystoscopy overuse common in surveillance of low-risk bladder Ca
Despite recommendations for low-intensity cystoscopic surveillance in low-risk non-muscle invasive bladder cancer patients, U.S. Department of Veterans Affairs providers overused cystoscopy in 75% of these patients, according to a study published in Urology (2019; 131:112-9).
“The variability in recommendations [for hematuria evaluation] and our study’s findings highlight implicit value judgments and a potentially high burden of harms not historically considered in many guidelines’ development process," says Matthew E. Nielsen, MD, MS.